Annovis Bio, Inc.
A clinical-stage drug platform company developing therapies for neurodegenerative diseases.
ANVS | US
Overview
Corporate Details
- ISIN(s):
- US03615A1088
- LEI:
- Country:
- United States of America
- Address:
- 101 LINDENWOOD DRIVE, SUITE 225, 19355 MALVERN
- Website:
- https://www.annovisbio.com/
Description
Annovis Bio, Inc. is a clinical-stage drug platform company that develops therapies for neurodegenerative diseases. The company's primary focus is on conditions such as Alzheimer's disease (AD) and Parkinson's disease (PD). Its lead product candidate, buntanetap, is a translational inhibitor designed to halt the death of nerve cells by targeting the synthesis of multiple neurotoxic proteins. The company's therapeutic approach aims to restore nerve cell function, with the goal of improving cognitive and motor abilities in patients suffering from neurodegeneration.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-08-06 00:00 |
AD & PD Data Updates - July 2024
|
English | 1.0 MB |
Automate Your Workflow. Get a real-time feed of all Annovis Bio, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Annovis Bio, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Annovis Bio, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
